Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors
December 20, 2022 08:00 ET
|
Erasca, Inc.
Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support...
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
December 13, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
December 09, 2022 07:34 ET
|
Erasca, Inc.
Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500...
Erasca Announces Pricing of Underwritten Offering of Common Stock
December 09, 2022 07:32 ET
|
Erasca, Inc.
SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
November 30, 2022 08:00 ET
|
Erasca, Inc.
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer Erasca previously signed...
Erasca to Present at Upcoming Investor Conferences
November 22, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Reports Third Quarter 2022 Financial Results and Business Updates
November 09, 2022 16:01 ET
|
Erasca, Inc.
Positive preliminary monotherapy data for ERAS-007 and ERAS-601 support ongoing and future combination trials Signed CTCSAs with Eli Lilly to supply cetuximab in combination with ERAS-601 and with...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
October 20, 2022 08:00 ET
|
Erasca, Inc.
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with palbociclib in patients with KRAS- and NRAS-mutant colorectal cancer and KRAS-mutant pancreatic cancer ...
Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium
October 12, 2022 08:00 ET
|
Erasca, Inc.
Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors show safe and tolerable profiles for combination development CNS-penetrant EGFR...
Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022
September 26, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...